- Conditions
- SLE, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus
- Interventions
- No Medical Intervention
- Other
- Lead sponsor
- Lupus Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Great Neck, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 483
matching trials from the live ClinicalTrials.gov search.
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19, Cell Therapy, Lupus, Lupus Nephritis (LN)
- Interventions
- CART19
- Biological
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Prasterone (GL701)
- Drug
- Lead sponsor
- Genelabs Technologies
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Los Angeles, California • Rancho Mirage, California + 18 more
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
- Interventions
- PiCASO Intervention Group, Sham Comparator: Attention Control Group
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 16 Years to 22 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Memantine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Autoimmune Diseases
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- belimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 2
- States / cities
- Wilmington, North Carolina
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis
- Interventions
- CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
- Drug · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Nephritis
- Interventions
- ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • La Palma, California • Orange, California + 20 more
- Conditions
- Refractory Autoimmune Diseases
- Interventions
- BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
- Genetic · Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Lupus
- Interventions
- BMS-986326, Placebo for BMS-986326
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more
- Conditions
- Systemic Lupus Erythematosus, Depression
- Interventions
- XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS, XCSITE100 Stimulator - Active Sham
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 100 mg SC
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Zostavax vaccine
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SLE Glomerulonephritis Syndrome, WHO Class V
- Interventions
- Acthar gel
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Systemic Lupus Erythematosus, Cutaneous Lupus
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- BOS161721, Placebo
- Drug
- Lead sponsor
- Boston Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Biological
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Interventions
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more